The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).

The metabolism of methylenedioxymethamphetamine (MDMA, "ecstasy") was examined in a microsomal preparation of the yeast Saccharomyces cerevisiae expressing human debrisoquine hydroxylase, CYP2D6. Only one product, dihydroxymethylamphetamine (DHMA), was detected in the incubation mixture, and this product accounted for all of the substrate consumption at low concentration (10 microM). Mean +/- SD values of apparent Km(microM) and Vmax (nmol/min per nmol P450) for the demethylenation of (+) and (-)-MDMA at low concentrations (1-100 microM) were 1.72, 0.12 and 6.45, 0.10 and 2.90, 0.10 and 7.61, 0.06, respectively. At high concentrations (> 1000 microM) substrate inhibition was noted, with Ki values of 14.2 and 28.2 mM, respectively, for the (+) and (-) enantiomers. Incubation of MDMA isomers with human liver microsomes indicated that their demethylenation is deficient in the poor metabolizer phenotype. Thus, MDMA is converted to the catecholamine DHMA by CYP2D6, and this may give rise to genetically-determined differences in toxicity.

[1]  G. Tucker,et al.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.

[2]  A. Cho,et al.  Aromatic hydroxylation of methylenedioxybenzene (MDB) and methylenedioxymethamphetamine (MDMA) by rabbit liver microsomes. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  F. Gonzalez,et al.  Molecular genetics of the debrisoquin‐sparteine polymorphism , 1991, Clinical pharmacology and therapeutics.

[4]  R. Bost,et al.  'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.

[5]  R. Foltz,et al.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.

[6]  E. Dybing,et al.  Oxidation of alpha-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: possible mechanism of methyldopa hepatitis. , 1976, Molecular pharmacology.

[7]  C. J. Schmidt,et al.  Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. , 1988, European journal of pharmacology.

[8]  G. Screaton,et al.  Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.

[9]  A. Cho,et al.  Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver. , 1992, Molecular pharmacology.

[10]  G. Tucker,et al.  Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. , 1992, Biochemical pharmacology.

[11]  A. Cho,et al.  Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects. , 1991, Journal of medicinal chemistry.

[12]  R. Tyndale,et al.  Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. , 1991, Molecular pharmacology.

[13]  A. Cho,et al.  The p-hydroxylation of amphetamine and phentermine by rat liver microsomes. , 1975, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  A. Winstock.  Chronic paranoid psychosis after misuse of MDMA. , 1991, BMJ.

[15]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[16]  I. Roots,et al.  Hydrogen peroxide in hepatic microsomes. , 1978, Methods in enzymology.

[17]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.

[18]  G. Ricaurte,et al.  Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. , 1992, Chemical research in toxicology.

[19]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[20]  A. Cho,et al.  Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. , 1992, Chemical research in toxicology.

[21]  D. Kelly,et al.  The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae. , 1991, Biochemical pharmacology.

[22]  K. E. Moore,et al.  Depression of behavior and the brain content of α-methylnorepinephrine and α-methyldopamine following the administration of α-methyldopa , 1971 .

[23]  P. Murphy,et al.  Aromatic hydroxylation of amphetamine with rat liver microsomes, perfused liver, and isolated hepatocytes. , 1978, Biochemical pharmacology.

[24]  R. Glennon,et al.  The effect of MDMA (“Ecstasy”) and its optical isomers on schedule-controlled responding in mice , 1987, Pharmacology Biochemistry and Behavior.